Close X
Attorney Spotlight

How does Jordana Nelson's prior experience as a general counsel inform her work with firm clients? Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

The M&A Advisor Winner 2017The M&A Advisor announced the winners of the 16th Annual M&A Advisor Awards on Monday, November 13 at the 2017 M&A Advisor Awards. Bass, Berry & Sims was named a winner in the two categories related to the following deals:

M&A Deal of the Year (from $1B-$5B) – Acquisition of CLARCOR Inc. by Parker Hannifin Corporation

Corporate/Strategic Deal of the Year (over $1B) – Acquisition of BNC Bancorp by Pinnacle Financial Partners

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Regulation A+

It seems that lately there has been a noticeable uptick in Regulation A+ activity, including several recent Reg A+ securities offerings where the stock now successfully trades on national exchanges. In light of this activity, we have published a set of FAQs about Regulation A+ securities offerings to help companies better understand this "mini-IPO" offering process, as well as pros and cons compared to a traditional underwritten IPO.

Read now

California Rule Change: Drug Labeling Requirements

Firm Publication

Publications

February 15, 2017

Recently, the California Board of Pharmacy announced changes to its drug labeling rules that will take effect on April 1, 2017. The Board of Pharmacy amended Section 1744 of Article 5 of Division 17 of Title 16 of the California Code of Regulations to require that a pharmacist notify patients, via a written label on the drug container, of the risk associated with any drug that (1) may impair a user's ability to operate a vehicle or vessel, or (2) poses a substantial risk to the person consuming the drug when taken in combination with alcohol.

In addition to identifying certain classes of drug products for which such a label must be included, the amended rule also requires that the pharmacist use his or her professional judgment to determine whether such a label must be included with any other prescription. The previous rule required that the patient be informed of relevant risks, but did not require that written notice of such risks be provided on the label. This updated provision supplements California's existing rules addressing "patient-centered labels" for prescription drugs. 

Pharmacies serving California patients should review their processes to ensure this written notice is included with any such drugs dispensed to a California patient. Should you have any questions, please contact one of the authors listed or any member of our Specialty Pharmacy & Pharmaceuticals team.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.